WO2004033028A2 - Phototherapy system and device - Google Patents

Phototherapy system and device Download PDF

Info

Publication number
WO2004033028A2
WO2004033028A2 PCT/US2003/031767 US0331767W WO2004033028A2 WO 2004033028 A2 WO2004033028 A2 WO 2004033028A2 US 0331767 W US0331767 W US 0331767W WO 2004033028 A2 WO2004033028 A2 WO 2004033028A2
Authority
WO
WIPO (PCT)
Prior art keywords
color
treatment
hght
light
array
Prior art date
Application number
PCT/US2003/031767
Other languages
French (fr)
Other versions
WO2004033028A3 (en
Inventor
Dong-Chune Christopher Chung
Abraham Totah
Bryan Flaherty
Original Assignee
Natus Medical Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/265,970 external-priority patent/US7131990B2/en
Application filed by Natus Medical Incorporated filed Critical Natus Medical Incorporated
Priority to AU2003282748A priority Critical patent/AU2003282748A1/en
Publication of WO2004033028A2 publication Critical patent/WO2004033028A2/en
Publication of WO2004033028A3 publication Critical patent/WO2004033028A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0621—Hyperbilirubinemia, jaundice treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0642—Irradiating part of the body at a certain distance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning

Definitions

  • This invention relates to devices and methods for the phototherapeutic treatment of illness and diseases.
  • Phototherapy is a promising clinical tool for the treatment for many conditions, including seasonal affective disorder, bulimia nervosa, herpes, psoriasis, sleep disorders, acne, and skin cancer.
  • Phototherapy is especially promising as a treatment for hyperbilirubinemia, a common condition affecting 60-70% of all full-term infants.
  • Hyperbilirubinemia is caused by the accumulation of excess bilirubin in the blood and skin of the infant. This excess bilirubin turns the skin and sclera a characteristic yellow color. If left untreated, extreme cases of hyperbilirubinemia can result in neurological insult (kernicterus) or even death.
  • a common treatment for hyperbilirubinemia is phototherapy, in which the infant is exposed to light in a range corresponding to the peak absorption spectra for bilirubin (blue-green, 400-520 ran). This light changes the form of the bilirubin to a different isomer that is more readily eliminated by the body.
  • LEDs light emitting diodes
  • the present invention is a phototherapy system with light sources covering at least two distinct spectral light regions.
  • the spectral light region of the first set of light sources is chosen for its phototherapeutic value. This spectral light region, which need not be a continuous part of the spectrum, will be referred to as the "treatment color.”
  • the spectral light region of the second set of light sources is chosen for its ability to mitigate any nausea or other discomfort from viewing the treatment color. This spectral light region will be referred to as the "balancing color.”
  • the treatment color is blue, and the balancing color is yellow. This embodiment can be used to be treat hyperbilirubinemia.
  • Fig. 1. is a perspective view of a device according to the present invention, with a stand.
  • Fig. 2. is a perspective view of a device according to the present invention, without a stand, and with the enclosure tilted up to reveal exemplary LED light sources.
  • Fig. 3 is a front view of a device according to the present invention, without a stand.
  • Fig. 4 is a back view of a device according to the present invention, without a stand.
  • Fig 5. is a side view of a device according to the present invention, without a stand.
  • Fig. 6 is a side view of a device according to the present invention, without a stand, and with the enclosure tilted up.
  • Fig. 7 is a side view of a device according to the present invention, with a stand.
  • Figs. 8a and 8b are schematic depictions of exemplary phototherapy arrays according to embodiments of the present invention.
  • Fig. 9 is a chromatidty table.
  • the present invention is a phototherapy system and device, including (i) an optional stand 10, (ii) an enclosure 30, and (iii) an array of light sources 40 in the enclosure 30.
  • the array includes treatment color light sources (such as blue) and balancing color light sources (such as yellow).
  • the optional stand 10 is used to hold the light sources over the subject.
  • the stand 10 may have wheels 12, a vertical extension 14, and a horizontal extension 16. It may also have height control means 18 to raise or lower the enclosure 30, and horizontal positioning means 20 to control the horizontal position of the enclosure 30.
  • the stand is optional, and other means can be used to hold the array of lights over the subject. For instance, the array can be clipped or fastened over a bassinet, incubator or bed. Depending on the light source used, the array 40 can be distant or very close to the subject.
  • the enclosure 30 can be mounted on the stand so that it can be easily tilted. (See Fig. 6).
  • the enclosure 30 simply provides structural support for the sockets or board which hold the array of light sources 40.
  • Fig. 2 shows the enclosure 30 with an LED board 42.
  • "enclosure” is defined to mean any structure that holds the light sources.
  • at the back of the enclosure there is an exhaust 32, a power entry module 34, attachment plate 36 to attach the enclosure to the stand 10, an air inlet 38, and a top surface 39.
  • the top surface 39 may angled to discourage the placement of spillable liquids on the top of the device.
  • the enclosure can be made of many materials, including but not limited to metal or various kinds of plastic or polyvinyl materials. Typically, the enclosure will be a rigid structure. However, it is possible to use a flexible enclosure to be used in embodiments in which the enclosure is wrapped around the subject.
  • the array of light sources 40 is a plurality of band-limited light sources, such as semiconductor light sources, LEDs 42, halogen lights, low-intensity lasers, etc.
  • the array can take a number of different forms, and the distribution of lights in the array can be uniform or nonuniform.
  • Switches are used to control the light sources, and in one embodiment, a switch 44 can provide for operation in either a high or low intensity mode.
  • a potentiometer could be added to provide more precise control or to provide a wider range of light intensity.
  • diffusers and other optical intensity adjustment devices can be used to adjust the intensity of the light.
  • an "optical intensity adjustment .device" is any device that can alter the intensity of emitted light.
  • the array includes light sources covering at least two different spectral light regions. See Fig. 8.
  • the first spectral light region - the treatment color — is chosen for its phototherapeutic value.
  • the treatment color can be blue, for use in treating hyperbilirubinemia.
  • Other exemplary treatment colors include fed for treatment of psoriasis.
  • the second spectral light region - the balancing color is chosen for its ability to modify perception of the treatment color and thereby mitigate the nausea or other negative effects that result from viewing the treatment color. For instance, some healthcare workers have reported nausea from exposure to blue light LEDs. It has been found through trial and error that interspersing yellow LEDs into an array of blue LEDs mitigates or eliminates that effect. Yellow light seems to relieve blue light nausea better than other colors. For purposes of this patent, “blue” light is in the range of 400 ran to 520 ran, and "yellow” light is in the range of 547 nm to 619 ran. Green, red, or orange light sources can also be used for the balancing color when blue light is used for the treatment light
  • the " balancing color can be determined by experimentation to gauge what color most effectively relieves the symptoms caused by the treatment color.
  • the balancing color may be the spectral light range that produces a perception of white or non-treatment color when combined with the treatment color.
  • a chromaticity table such as the one provided as Figure 9, can be used to find the appropriate balancing color, by drawing a line from the treatment color through the central point indicating white light, and then determining where the line intersects the color line.
  • balancing colors can be also used.
  • red and yellow light can be used to balance the blue light used to treat hyperbilirubinemia.
  • intensity of the balancing color or colors can be adjusted to achieve the desired effect.
  • a sufficient amount of balancing color light is required.
  • a ratio of about 3 blue LEDs to 1 yellow LEDs of equal intensity has been found sufficient.
  • the appropriate ratio will depend on a number of factors, including the intensity of both the treatment LEDs and the balancing LEDs, and on the color perception that is sought.
  • the balancing color light sources can be arranged in the array in a number of ways, including random distribution, various uniform distributions, distribution about the periphery of the array, and even placement in a separate array or enclosure.
  • Exemplary arrays are provided in Figures 8a and 8b. In these figures, a target light of red LEDs is also shown,
  • narrow-band or limited spectral range light sources including semiconductor light sources, LEDs and low-intensity lasers.
  • limited spectral range light source will be used to generically refer to any light source that emits light from any spectral range except the range that includes all visible colors, i.e. white light.
  • approximately 1000 blue-green (420 - 500 nm) LEDs can be used to treat hyperbilirubinemia, along with 320 yellow LEDs.
  • Such LEDs are commercially available from CREE, Inc. (4600 Silicon Drive, Durham, NC 27703) and Nichia America Corporation (3775 Hempland Road, Mountville, Pennsylvania 17554).
  • the number of light sources in the array will vary based on their intensity and on the nature of the phototherapeutic treatment.
  • the light sources 40 would shine down on the subject. However, they can also be oriented upwards, and bounce off an optional reflector on the enclosure. Such a reflector can be curved into a convex formation, to diffuse the light away from the center of the subject, or to otherwise alter the intensity, distribution, or light properties of the array.
  • the light sources can be arranged to shine from the side, such as through a transparent bassinet, or from the bottom, or any combination thereof.
  • Both the treatment color light sources and the balancing color light sources may be illuminated continuously or discontinuously, and the present invention is not Hmited by the duration, frequency, or pattern of illumination for either or both set of light sources.
  • the lights may illuminated synchronously, asynchronously, in a staggered manner, in a random manner, or in accordance with a predefined frequency or duty cycle (ratio of illuminated time to non-illuminated time). In one embodiment, a duty cycle of below 0.5 is used.
  • the subject may be placed under the phototherapy device, and both the treatment color and balancing color light sources may be iUuminated simultaneously.
  • the subject will then receive phototherapy, and the healthcare workers admiriistering the treatment may not feel the nausea that sometimes results from exposure to a single color light such as blue.
  • the balancing color changes the perception of the health care workers so that instead of perceiving only the treatment color, the workers perceive a blended, balanced, or alternative color.
  • the intensity of the balancing color can be adjusted as necessary to achieve the desired balanced or altered perception.

Abstract

A phototherapy system and device is disclosed, including an array (40) of light sources from at least two distinct spectral light regions. The first spectral light region represents the treatment color, and thus is chosen for its phototherapeutic value. For instance, blue light may be the treatment color for hyperbilirubinemia. The second spectral light region represents the balancing color, and is chosen for its ability to mitigate discomfort that may be caused by viewing the treatment color. When blue is the treatment color, yellow has been found to be an effective balancing color.

Description

DESCRIPTION
PHOTOTHERAPY SYSTEM AND DEVICE
Inventors: Dong-Chune Christopher Chung, M.D., Abraham Totah, and Bryan
Flaherty, Ph.D.
Technical Field
This invention relates to devices and methods for the phototherapeutic treatment of illness and diseases.
Background
Phototherapy is a promising clinical tool for the treatment for many conditions, including seasonal affective disorder, bulimia nervosa, herpes, psoriasis, sleep disorders, acne, and skin cancer.
Phototherapy is especially promising as a treatment for hyperbilirubinemia, a common condition affecting 60-70% of all full-term infants. Hyperbilirubinemia is caused by the accumulation of excess bilirubin in the blood and skin of the infant. This excess bilirubin turns the skin and sclera a characteristic yellow color. If left untreated, extreme cases of hyperbilirubinemia can result in neurological insult (kernicterus) or even death. A common treatment for hyperbilirubinemia is phototherapy, in which the infant is exposed to light in a range corresponding to the peak absorption spectra for bilirubin (blue-green, 400-520 ran). This light changes the form of the bilirubin to a different isomer that is more readily eliminated by the body.
A number of different light sources can be used for phototherapy. Traditionally, broadband sources have been used, such as fluorescent, halogen, or incandescent light. However, it has been recently suggested that light emitting diodes (LEDs) can be an effective phototherapeutic light source.
Blue LEDs have been effectively used to treat hyperbilirubinemia, but some individuals report a f eeling of nausea or discomfort from prolonged exposure to blue light. Thus, there is a need for a method of relieving the discomfort these individuals feel, without compromising the effectiveness of the phototherapy. Sttπunary Disclosure of the Invention
The present invention is a phototherapy system with light sources covering at least two distinct spectral light regions. The spectral light region of the first set of light sources is chosen for its phototherapeutic value. This spectral light region, which need not be a continuous part of the spectrum, will be referred to as the "treatment color." The spectral light region of the second set of light sources is chosen for its ability to mitigate any nausea or other discomfort from viewing the treatment color. This spectral light region will be referred to as the "balancing color." In one embodiment, the treatment color is blue, and the balancing color is yellow. This embodiment can be used to be treat hyperbilirubinemia.
Brief Description of the Drawings
Fig. 1. is a perspective view of a device according to the present invention, with a stand.
Fig. 2. is a perspective view of a device according to the present invention, without a stand, and with the enclosure tilted up to reveal exemplary LED light sources.
Fig. 3 is a front view of a device according to the present invention, without a stand.
Fig. 4 is a back view of a device according to the present invention, without a stand.
Fig 5. is a side view of a device according to the present invention, without a stand.
Fig. 6 is a side view of a device according to the present invention, without a stand, and with the enclosure tilted up.
Fig. 7 is a side view of a device according to the present invention, with a stand.
Figs. 8a and 8b are schematic depictions of exemplary phototherapy arrays according to embodiments of the present invention.
Fig. 9 is a chromatidty table.
Detailed Description, Including Best Mode
The present invention is a phototherapy system and device, including (i) an optional stand 10, (ii) an enclosure 30, and (iii) an array of light sources 40 in the enclosure 30. The array includes treatment color light sources (such as blue) and balancing color light sources (such as yellow).
As depicted in Figs. 1 and 7, the optional stand 10 is used to hold the light sources over the subject. The stand 10 may have wheels 12, a vertical extension 14, and a horizontal extension 16. It may also have height control means 18 to raise or lower the enclosure 30, and horizontal positioning means 20 to control the horizontal position of the enclosure 30. The stand is optional, and other means can be used to hold the array of lights over the subject. For instance, the array can be clipped or fastened over a bassinet, incubator or bed. Depending on the light source used, the array 40 can be distant or very close to the subject.
The enclosure 30 can be mounted on the stand so that it can be easily tilted. (See Fig. 6). The enclosure 30 simply provides structural support for the sockets or board which hold the array of light sources 40. For instance, Fig. 2 shows the enclosure 30 with an LED board 42. The precise form of the enclosure is irrelevant to the present invention. Indeed, for purposes of this patent, "enclosure" is defined to mean any structure that holds the light sources. As shown in Figs. 2 & 4, at the back of the enclosure there is an exhaust 32, a power entry module 34, attachment plate 36 to attach the enclosure to the stand 10, an air inlet 38, and a top surface 39. The top surface 39 may angled to discourage the placement of spillable liquids on the top of the device.
The enclosure can be made of many materials, including but not limited to metal or various kinds of plastic or polyvinyl materials. Typically, the enclosure will be a rigid structure. However, it is possible to use a flexible enclosure to be used in embodiments in which the enclosure is wrapped around the subject.
The array of light sources 40 is a plurality of band-limited light sources, such as semiconductor light sources, LEDs 42, halogen lights, low-intensity lasers, etc. The array can take a number of different forms, and the distribution of lights in the array can be uniform or nonuniform.
Switches are used to control the light sources, and in one embodiment, a switch 44 can provide for operation in either a high or low intensity mode. Alternatively, a potentiometer could be added to provide more precise control or to provide a wider range of light intensity. Also, diffusers and other optical intensity adjustment devices can be used to adjust the intensity of the light. For purposes of this patent, an "optical intensity adjustment .device" is any device that can alter the intensity of emitted light.
The array includes light sources covering at least two different spectral light regions. See Fig. 8. The first spectral light region - the treatment color — is chosen for its phototherapeutic value. Thus, in one embodiment, the treatment color can be blue, for use in treating hyperbilirubinemia. Other exemplary treatment colors include fed for treatment of psoriasis.
The second spectral light region - the balancing color — is chosen for its ability to modify perception of the treatment color and thereby mitigate the nausea or other negative effects that result from viewing the treatment color. For instance, some healthcare workers have reported nausea from exposure to blue light LEDs. It has been found through trial and error that interspersing yellow LEDs into an array of blue LEDs mitigates or eliminates that effect. Yellow light seems to relieve blue light nausea better than other colors. For purposes of this patent, "blue" light is in the range of 400 ran to 520 ran, and "yellow" light is in the range of 547 nm to 619 ran. Green, red, or orange light sources can also be used for the balancing color when blue light is used for the treatment light
For other phototherapeutic colors, the "balancing color can be determined by experimentation to gauge what color most effectively relieves the symptoms caused by the treatment color. The balancing color may be the spectral light range that produces a perception of white or non-treatment color when combined with the treatment color. A chromaticity table, such as the one provided as Figure 9, can be used to find the appropriate balancing color, by drawing a line from the treatment color through the central point indicating white light, and then determining where the line intersects the color line.
Multiple balancing colors can be also used. Thus, for instance, red and yellow light can be used to balance the blue light used to treat hyperbilirubinemia. Additionally, the intensity of the balancing color or colors can be adjusted to achieve the desired effect.
In order to adequately modify the phototherapeutic color, a sufficient amount of balancing color light is required. In one embodiment, a ratio of about 3 blue LEDs to 1 yellow LEDs of equal intensity has been found sufficient. Of course, the appropriate ratio will depend on a number of factors, including the intensity of both the treatment LEDs and the balancing LEDs, and on the color perception that is sought.
The balancing color light sources can be arranged in the array in a number of ways, including random distribution, various uniform distributions, distribution about the periphery of the array, and even placement in a separate array or enclosure. Exemplary arrays are provided in Figures 8a and 8b. In these figures, a target light of red LEDs is also shown,
The present invention can be practiced with many different types of narrow-band or limited spectral range light sources, including semiconductor light sources, LEDs and low-intensity lasers. For purposes of this patent, the term "limited spectral range light source" will be used to generically refer to any light source that emits light from any spectral range except the range that includes all visible colors, i.e. white light. In one embodiment, approximately 1000 blue-green (420 - 500 nm) LEDs can be used to treat hyperbilirubinemia, along with 320 yellow LEDs. Such LEDs are commercially available from CREE, Inc. (4600 Silicon Drive, Durham, NC 27703) and Nichia America Corporation (3775 Hempland Road, Mountville, Pennsylvania 17554). The number of light sources in the array will vary based on their intensity and on the nature of the phototherapeutic treatment.
Typically, the light sources 40 would shine down on the subject. However, they can also be oriented upwards, and bounce off an optional reflector on the enclosure. Such a reflector can be curved into a convex formation, to diffuse the light away from the center of the subject, or to otherwise alter the intensity, distribution, or light properties of the array.
Also, the light sources can be arranged to shine from the side, such as through a transparent bassinet, or from the bottom, or any combination thereof.
Both the treatment color light sources and the balancing color light sources may be illuminated continuously or discontinuously, and the present invention is not Hmited by the duration, frequency, or pattern of illumination for either or both set of light sources. Thus, the lights may illuminated synchronously, asynchronously, in a staggered manner, in a random manner, or in accordance with a predefined frequency or duty cycle (ratio of illuminated time to non-illuminated time). In one embodiment, a duty cycle of below 0.5 is used.
In operation, the subject may be placed under the phototherapy device, and both the treatment color and balancing color light sources may be iUuminated simultaneously. The subject will then receive phototherapy, and the healthcare workers admiriistering the treatment may not feel the nausea that sometimes results from exposure to a single color light such as blue. The balancing color changes the perception of the health care workers so that instead of perceiving only the treatment color, the workers perceive a blended, balanced, or alternative color. The intensity of the balancing color can be adjusted as necessary to achieve the desired balanced or altered perception.
One skilled in the art will appreciate that the present invention can be practiced through a number of embodiments, including but not limited to those specifically described in this patent. Therefore, the embodiments, dimensions, and materials described in this patent are presented for illustration, not to limit the scope of the claims.

Claims

CLAIMSWe daim:
1.) A method of mitigating effects on human health or comfort from exposure to a limited spectral range treatment color Hght source, comprising causing a subject to view Hght from a first limited spectral range balancing color light source while said subject is viewing light from said treatment color light source.
2.) The method according to daim 1, additionally comprising adjusting the intensity of the balandng color light source to effectively relieve the effects on human health or comfort from exposure to said treatment color light source.
3.) The method according to daim 1, additionally comprising causing the subject to view light from a second balancing color Hght source while said subject is viewing light from said treatment color Hght source.
4.) The method according to daim 1, wherein both said treatment color Hght source and said first balancing color Hght source are illuminated continuously during phototherapy.
5.) The method according to daim 1, wherein both said treatment color Hght source and said first balancing color light source are illuminated discontinuously during phototherapy.
6.) The method according to claim 1, wherein one of said treatment color Hght source and said balancing color light source is illuminated discontinuously during phototherapy, and the other is illuminated continuously.
7.) The method according to claim 1, 2, 3, , 5, or 6, wherein said treatment color light source emits substantiaHy blue light, and wherein said first limited spectral range balandng color light source emits Hght that is substantially yellow, orange, red, or green.
8.) The method according to daim 7, wherein said first limited spectral range balancing color Hght source emits Hght that is substantially yeHow.
9.) A phototherapy system, comprising a limited spectral range treatment Hght source emitting Hght of a treatment color; and a first limited spectral range balancing Hght source emitting light of a first balandng color.
10.) The system according to claim 9, additionaHy comprising an enclosure for holding said treatment light source and said balandng light source.
11.) The system according to daim 9 or 10, wherein said treatment color is blue.
12.) The system according to claim 11, wherein said balandng color is yellow.
13.) The system according to claim 12, additionally comprising a second limited spectral range balandng Hght source emitting Hght of a second balancing color.
14.) The system according to claim 11, wherein said treatment light source is an LED.
15.) The system according to daim 11, wherein said balandng light source is an LED.
16.) The system according to claim 14, wherein said balandng light source is an LED.
17.) The system according to daim 9, wherein there are a plurality of said treatment light sources and said balandng light sources, and wherein the ratio of said treatment light sources to said balandng Hght sources is approximately 3: 1.
18.) The system according to daim 12, wherein there are a pluraHty of said treatment Hght sources and said balancing light sources, and wherein the ratio of intensity of said treatment Hght sources to said balancing lights sources is approximately 3: 1.
19.) An array of phototherapeutic lights sources, comprising Hmited spectral range lights of a treatment color and limited 'Spectral range lights of a balancing color, wherein said balandng color is chosen for its abiHty to mitigate the health or comfort effects on humans from viewing said treatment color.
20.) The array according to daim 19, wherein said treatment color is blue and said balandng color is yeHow.
21.) A phototherapy system, comprising: a first array of limited spectral range Hght sources chosen for their phototherapeutic value, said first array of Hght sources having an intensity when illuminated; and means for adjusting the intensity of said first array of light sources.
22.) The system according to daim 21, wherein said means for adjusting the intensity of said first array of light sources cqmprises a potentiometer.
23.) The system according to daim 21,-wherein said means for adjusting the intensity of said first array of light sources comprises a switch for adjusting the intensity between at least two intensity modes.
24.) The system according to claim 21, wherein said means for adjusting the intensity of said first array of Hght sources comprises an optical intensity adjustment, device.
25.) The system according to claim 24, wherein said optical intensity adjustment device is a diffuser.
26.) The system according to claim 21, 22, 23, 24, or 25 additionally comprising a second array of limited spectral range light sources chosen for their ability to mitigate negative effects on human health or comfort from viewing said first array; and means for adjusting the intensity of said second array of light sources.
PCT/US2003/031767 2002-10-07 2003-10-07 Phototherapy system and device WO2004033028A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003282748A AU2003282748A1 (en) 2002-10-07 2003-10-07 Phototherapy system and device

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/265,970 2002-10-07
US10/265,970 US7131990B2 (en) 2002-10-07 2002-10-07 Phototherapy system and device
US10/651,906 US7438719B2 (en) 2002-10-07 2003-08-29 Phototherapy system and device
US10/651,906 2003-08-29

Publications (2)

Publication Number Publication Date
WO2004033028A2 true WO2004033028A2 (en) 2004-04-22
WO2004033028A3 WO2004033028A3 (en) 2004-05-13

Family

ID=32095663

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/031768 WO2004033029A2 (en) 2002-10-07 2003-10-07 Phototherapy system and device
PCT/US2003/031767 WO2004033028A2 (en) 2002-10-07 2003-10-07 Phototherapy system and device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031768 WO2004033029A2 (en) 2002-10-07 2003-10-07 Phototherapy system and device

Country Status (2)

Country Link
AU (2) AU2003282748A1 (en)
WO (2) WO2004033029A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025671A1 (en) * 2003-09-17 2005-03-24 Djalma Luiz Rodrigues A phototherapy equipment, particularly for the treatment of hyperbilirubinemia
WO2009056838A1 (en) * 2007-10-31 2009-05-07 University Of Strathclyde Lighting device
US9333274B2 (en) 2014-07-31 2016-05-10 Vital Vio, Inc. Disinfecting light fixture
US9439989B2 (en) 2014-07-31 2016-09-13 Vital Vio, Inc. Disinfecting light fixture
US9927097B2 (en) 2015-07-30 2018-03-27 Vital Vio Inc. Single diode disinfection
US10309614B1 (en) 2017-12-05 2019-06-04 Vital Vivo, Inc. Light directing element
US10357582B1 (en) 2015-07-30 2019-07-23 Vital Vio, Inc. Disinfecting lighting device
US10363325B2 (en) 2015-06-26 2019-07-30 Kenall Manufacturing Company Lighting device that deactivates dangerous pathogens while providing visually appealing light
US10413626B1 (en) 2018-03-29 2019-09-17 Vital Vio, Inc. Multiple light emitter for inactivating microorganisms
US10456485B1 (en) 2015-06-26 2019-10-29 Kenall Manufacturing Company Single-emitter lighting device that outputs a minimum amount of power to produce integrated radiance values sufficient for deactivating pathogens
US10617774B2 (en) 2017-12-01 2020-04-14 Vital Vio, Inc. Cover with disinfecting illuminated surface
US10918747B2 (en) 2015-07-30 2021-02-16 Vital Vio, Inc. Disinfecting lighting device
US10953117B2 (en) 2005-07-29 2021-03-23 University Of Strathclyde Inactivation of gram-positive bacteria
US11273324B2 (en) 2015-07-14 2022-03-15 Illumipure Corp LED structure and luminaire for continuous disinfection
US11369704B2 (en) 2019-08-15 2022-06-28 Vyv, Inc. Devices configured to disinfect interiors
US11499707B2 (en) 2020-04-13 2022-11-15 Calyxpure, Inc. Light fixture having a fan and ultraviolet sterilization functionality
US11541135B2 (en) 2019-06-28 2023-01-03 Vyv, Inc. Multiple band visible light disinfection
US11639897B2 (en) 2019-03-29 2023-05-02 Vyv, Inc. Contamination load sensing device
US11759540B2 (en) 2021-05-11 2023-09-19 Calyxpure, Inc. Portable disinfection unit
US11878084B2 (en) 2019-09-20 2024-01-23 Vyv, Inc. Disinfecting light emitting subcomponent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045575A (en) * 1997-09-10 2000-04-04 Amt, Inc. Therapeutic method and internally illuminated garment for the management of disorders treatable by phototherapy
US6166496A (en) * 1997-08-26 2000-12-26 Color Kinetics Incorporated Lighting entertainment system
US6290713B1 (en) * 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy
US6596016B1 (en) * 1997-03-27 2003-07-22 The Board Of Trustees Of The Leland Stanford Junior University Phototherapy of jaundiced newborns using garments containing semiconductor light-emitting devices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5299109A (en) * 1992-11-10 1994-03-29 High Lites, Inc. LED exit light fixture
JP3866858B2 (en) * 1998-04-30 2007-01-10 株式会社ニデック Laser therapy device
US6414801B1 (en) * 1999-01-14 2002-07-02 Truck-Lite Co., Inc. Catadioptric light emitting diode assembly

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596016B1 (en) * 1997-03-27 2003-07-22 The Board Of Trustees Of The Leland Stanford Junior University Phototherapy of jaundiced newborns using garments containing semiconductor light-emitting devices
US6166496A (en) * 1997-08-26 2000-12-26 Color Kinetics Incorporated Lighting entertainment system
US6045575A (en) * 1997-09-10 2000-04-04 Amt, Inc. Therapeutic method and internally illuminated garment for the management of disorders treatable by phototherapy
US6290713B1 (en) * 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025671A1 (en) * 2003-09-17 2005-03-24 Djalma Luiz Rodrigues A phototherapy equipment, particularly for the treatment of hyperbilirubinemia
US8202307B2 (en) 2003-09-17 2012-06-19 Djalma Luiz Rodrigues Phototherapy equipment for the treatment of hyperbilirubinemia and other diseases
US11730838B2 (en) 2005-07-29 2023-08-22 University Of Strathclyde Inactivation of gram-positive bacteria
US10953117B2 (en) 2005-07-29 2021-03-23 University Of Strathclyde Inactivation of gram-positive bacteria
WO2009056838A1 (en) * 2007-10-31 2009-05-07 University Of Strathclyde Lighting device
US8398264B2 (en) 2007-10-31 2013-03-19 University Of Strathclyde Lighting device
US9333274B2 (en) 2014-07-31 2016-05-10 Vital Vio, Inc. Disinfecting light fixture
US9439989B2 (en) 2014-07-31 2016-09-13 Vital Vio, Inc. Disinfecting light fixture
US10823369B2 (en) 2015-06-26 2020-11-03 Kenall Manufacturing Company Lighting device that deactivates dangerous pathogens while providing visually appealing light
US11054109B2 (en) 2015-06-26 2021-07-06 Kenall Manufacturing Company Single-emitter lighting device that outputs a minimum amount of power to produce integrated radiance values sufficient for deactivating pathogens
US11493183B2 (en) 2015-06-26 2022-11-08 Kenall Manufacturing Company Method of providing doses of light sufficient to deactivate dangerous pathogens throughout a volumetric space over a period of time
US10434202B2 (en) 2015-06-26 2019-10-08 Kenall Manufacturing Company Lighting device that deactivates dangerous pathogens while providing visually appealing light
US10456485B1 (en) 2015-06-26 2019-10-29 Kenall Manufacturing Company Single-emitter lighting device that outputs a minimum amount of power to produce integrated radiance values sufficient for deactivating pathogens
US11324843B2 (en) 2015-06-26 2022-05-10 Kenall Manufacturing Company Lighting device that deactivates dangerous pathogens while providing visually appealing light
US10617775B2 (en) 2015-06-26 2020-04-14 Kenall Manufacturing Company Lighting device that deactivates dangerous pathogens while providing visually appealing light
US10363325B2 (en) 2015-06-26 2019-07-30 Kenall Manufacturing Company Lighting device that deactivates dangerous pathogens while providing visually appealing light
US10765765B2 (en) 2015-06-26 2020-09-08 Kenall Manufacturing Company Single-emitter lighting device that outputs a minimum amount of power to produce integrated radiance values sufficient for deactivating pathogens
US11054110B2 (en) 2015-06-26 2021-07-06 Kenall Manufacturing Company Single-emitter lighting device that outputs a minimum amount of power to produce integrated radiance values sufficient for deactivating pathogens
US11273324B2 (en) 2015-07-14 2022-03-15 Illumipure Corp LED structure and luminaire for continuous disinfection
US11713851B2 (en) 2015-07-30 2023-08-01 Vyv, Inc. Single diode disinfection
US10918747B2 (en) 2015-07-30 2021-02-16 Vital Vio, Inc. Disinfecting lighting device
US10753575B2 (en) 2015-07-30 2020-08-25 Vital Vio, Inc. Single diode disinfection
US9927097B2 (en) 2015-07-30 2018-03-27 Vital Vio Inc. Single diode disinfection
US10357582B1 (en) 2015-07-30 2019-07-23 Vital Vio, Inc. Disinfecting lighting device
US10835627B2 (en) 2017-12-01 2020-11-17 Vital Vio, Inc. Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related method
US10617774B2 (en) 2017-12-01 2020-04-14 Vital Vio, Inc. Cover with disinfecting illuminated surface
US11426474B2 (en) 2017-12-01 2022-08-30 Vyv, Inc. Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related methods
US10309614B1 (en) 2017-12-05 2019-06-04 Vital Vivo, Inc. Light directing element
US11395858B2 (en) 2018-03-29 2022-07-26 Vyv, Inc. Multiple light emitter for inactivating microorganisms
US10806812B2 (en) 2018-03-29 2020-10-20 Vital Vio, Inc. Multiple light emitter for inactivating microorganisms
US10413626B1 (en) 2018-03-29 2019-09-17 Vital Vio, Inc. Multiple light emitter for inactivating microorganisms
US11639897B2 (en) 2019-03-29 2023-05-02 Vyv, Inc. Contamination load sensing device
US11541135B2 (en) 2019-06-28 2023-01-03 Vyv, Inc. Multiple band visible light disinfection
US11717583B2 (en) 2019-08-15 2023-08-08 Vyv, Inc. Devices configured to disinfect interiors
US11369704B2 (en) 2019-08-15 2022-06-28 Vyv, Inc. Devices configured to disinfect interiors
US11878084B2 (en) 2019-09-20 2024-01-23 Vyv, Inc. Disinfecting light emitting subcomponent
US11499707B2 (en) 2020-04-13 2022-11-15 Calyxpure, Inc. Light fixture having a fan and ultraviolet sterilization functionality
US11759540B2 (en) 2021-05-11 2023-09-19 Calyxpure, Inc. Portable disinfection unit

Also Published As

Publication number Publication date
AU2003279168A1 (en) 2004-05-04
AU2003282748A8 (en) 2004-05-04
WO2004033029A3 (en) 2004-06-24
AU2003282748A1 (en) 2004-05-04
AU2003279168A8 (en) 2004-05-04
WO2004033029A2 (en) 2004-04-22
WO2004033028A3 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
US7438719B2 (en) Phototherapy system and device
WO2004033028A2 (en) Phototherapy system and device
US10363434B2 (en) LED therapy bed
US20190232081A1 (en) Phototherapy device for the treatment of hyperbilirubinemia
EP3362145B1 (en) Adjustable illuminator for photodynamic therapy and diagnosis
KR20090055891A (en) Led radiator for skin
JP2022527540A (en) Irradiation modules, devices and methods for irradiating medical and cosmetic radiation
WO2004024234A1 (en) Radiating device
US7087074B2 (en) Light therapy apparatus
TWM623245U (en) Head illumination device
US11478657B1 (en) LED therapy bed
US20190275348A1 (en) Photonic Treatment Apparatus
TWI788004B (en) Head lighting device
EP3419720B1 (en) Led therapy bed
US20220379136A1 (en) Body irradiating device
WO2023031619A1 (en) Phototherapy mask

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP